These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32317147)

  • 21. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by
    Jahn U; Ilan E; Velikyan I; Fröss-Baron K; Lubberink M; Sundin A
    EJNMMI Res; 2021 Nov; 11(1):118. PubMed ID: 34822040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammation-Based Index and
    Pauwels E; Van Binnebeek S; Vandecaveye V; Baete K; Vanbilloen H; Koole M; Mottaghy FM; Haustermans K; Clement PM; Nackaerts K; Van Cutsem E; Verslype C; Deroose CM
    J Nucl Med; 2020 Jul; 61(7):1014-1020. PubMed ID: 31806775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of
    Sawicki LM; Deuschl C; Beiderwellen K; Ruhlmann V; Poeppel TD; Heusch P; Lahner H; Führer D; Bockisch A; Herrmann K; Forsting M; Antoch G; Umutlu L
    Eur Radiol; 2017 Oct; 27(10):4091-4099. PubMed ID: 28439648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT?
    Zemczak A; Kołodziej M; Gut P; Królicki L; Kos-Kudła B; Kamiński G; Ruchała M; Pawlak D; Kunikowska J
    Endokrynol Pol; 2020; 71(3):240-248. PubMed ID: 32293704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multimodal Imaging of 2-Cycle PRRT with
    Albrecht J; Exner S; Grötzinger C; Prasad S; Konietschke F; Beindorff N; Kühl AA; Prasad V; Brenner W; Koziolek EJ
    J Nucl Med; 2021 Mar; 62(3):393-398. PubMed ID: 32859703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraindividual comparison of
    Ouvrard E; Chevalier E; Addeo P; Sahakian N; Detour J; Goichot B; Bachellier P; Karcher G; Taïeb D; Imperiale A
    Clin Endocrinol (Oxf); 2021 Jan; 94(1):66-73. PubMed ID: 32790887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using
    Ilan E; Velikyan I; Sandström M; Sundin A; Lubberink M
    J Nucl Med; 2020 Feb; 61(2):217-221. PubMed ID: 31302632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.
    Van Binnebeek S; Vanbilloen B; Baete K; Terwinghe C; Koole M; Mottaghy FM; Clement PM; Mortelmans L; Bogaerts K; Haustermans K; Nackaerts K; Van Cutsem E; Verslype C; Verbruggen A; Deroose CM
    Eur Radiol; 2016 Mar; 26(3):900-9. PubMed ID: 26162577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relevance of Volumetric Parameters Applied to [
    Urso L; Castello A; Treglia G; Panareo S; Nieri A; Rambaldi I; Caracciolo M; Ortolan N; Uccelli L; Cittanti C; Castellani M; Bartolomei M
    Diagnostics (Basel); 2023 Feb; 13(4):. PubMed ID: 36832093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: Evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CT.
    Schreiter NF; Bartels AM; Froeling V; Steffen I; Pape UF; Beck A; Hamm B; Brenner W; Röttgen R
    Radiol Oncol; 2014 Dec; 48(4):339-47. PubMed ID: 25435846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Limited Value of Ga-68-DOTATOC-PET-CT in Routine Screening of Patients with Multiple Endocrine Neoplasia Type 1.
    Albers MB; Librizzi D; Lopez CL; Manoharan J; Apitzsch JC; Slater EP; Bollmann C; Kann PH; Bartsch DK
    World J Surg; 2017 Jun; 41(6):1521-1527. PubMed ID: 28138732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Diagnostic Sensitivity and Quantitative Indices Between (68)Ga-DOTATOC PET/CT and (111)In-Pentetreotide SPECT/CT in Neuroendocrine Tumors: a Preliminary Report.
    Lee I; Paeng JC; Lee SJ; Shin CS; Jang JY; Cheon GJ; Lee DS; Chung JK; Kang KW
    Nucl Med Mol Imaging; 2015 Dec; 49(4):284-90. PubMed ID: 26550047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 64Cu-DOTATATE for Noninvasive Assessment of Atherosclerosis in Large Arteries and Its Correlation with Risk Factors: Head-to-Head Comparison with 68Ga-DOTATOC in 60 Patients.
    Malmberg C; Ripa RS; Johnbeck CB; Knigge U; Langer SW; Mortensen J; Oturai P; Loft A; Hag AM; Kjær A
    J Nucl Med; 2015 Dec; 56(12):1895-900. PubMed ID: 26429961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG-Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin.
    Binse I; Poeppel TD; Ruhlmann M; Ezziddin S; Görges R; Sabet A; Beiderwellen K; Bockisch A; Rosenbaum-Krumme SJ
    J Nucl Med; 2016 Oct; 57(10):1512-1517. PubMed ID: 27033897
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Bélissant Benesty O; Nataf V; Ohnona J; Michaud L; Zhang-Yin J; Bertherat J; Chanson P; Reznik Y; Talbot JN; Montravers F
    Endocrine; 2020 Mar; 67(3):708-717. PubMed ID: 31583575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parametric Net Influx Rate Images of
    Ilan E; Sandström M; Velikyan I; Sundin A; Eriksson B; Lubberink M
    J Nucl Med; 2017 May; 58(5):744-749. PubMed ID: 27789716
    [No Abstract]   [Full Text] [Related]  

  • 39. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
    Srirajaskanthan R; Kayani I; Quigley AM; Soh J; Caplin ME; Bomanji J
    J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
    Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
    J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.